SEC Form S-4/A filed by SPK Acquisition Corp. (Amendment)
$SPK
Consumer Electronics/Appliances
Industrials
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
RW - SPK Acquisition Corp. (0001848097) (Filer)
25-NSE - SPK Acquisition Corp. (0001848097) (Subject)
8-K/A - SPK Acquisition Corp. (0001848097) (Filer)
4 - SPK Acquisition Corp. (0001848097) (Issuer)
3 - SPK Acquisition Corp. (0001848097) (Issuer)
NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a special purpose acquisition company ("SPAC"), today announced a joint presentation to discuss the proposed transaction and provide a corporate update. The presentation can be accessed by clicking the link here or by visiting Varian Bio's investor section of its website at www.varianbio.com. Transaction Overview Pursuant to the merger agreement, Varian Bio will merge with a wholly owned subsidiary of SPK, with Varian Bio being the surviving
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec